DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.message sent
email sent successfully
You are receiving this because you have an account on www.oneGRAVESvoice.com | ||
To unsubscribe from these emails, click here |
Trusted Resources: News & Meetings
Latest announcements and gatherings
New Data from Teprotumumab Phase 3 OPTIC Study Shows Significantly Reduced Double Vision and Improved Quality of Life for People With Active Thyroid Eye Disease
Horizon Therapeutics plc today announced new data from the Phase 3 OPTIC confirmatory clinical trial showing that teprotumumab provided significant benefit on several devastating effects of active thyroid eye disease (TED) compared with placebo, including diplopia (double vision), quality of life (QoL) and clinical activity score (CAS). These data were presented during the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) 50th Anniversary 2019 Fall Scientific Symposium, and build upon data presented earlier this year that demonstrated the significant benefit of teprotumumab on proptosis (bulging eyes).
Teprotumumab is an investigational medicine for the treatment of active TED and is currently under review by the U.S. Food and Drug Administration (FDA). The teprotumumab Biologics License Application (BLA) was recently granted Priority Review by the FDA and if approved, teprotumumab would be the first FDA-approved medicine for the treatment of active TED. The Prescription Drug User Fee Act (PDUFA) goal date is March 8, 2020.


Related Content
-
Evidence & EducationAdvances in the Pharmacological Treatment of Graves’ OrbitopathyGraves' orbitopathy has a deteriorating ...
-
Evidence & EducationSensitivity and Responsiveness of the Patient-Reported TED-QOL to Rehabilitative Surgery in Thyroid Eye DiseaseWe tested the sensitivity and responsive...
-
People & PlacesPrem Subramanian, MD, PhDPrem S. Subramanian is the Professor of ...
-
Videos & VisualsCoping Psychologically with Thyroid Eye Diseasehttps://www.youtube.com/watch?v=A-pjRWHj...
-
Evidence & EducationManagement of Graves’ Thyroidal and Extrathyroidal Disease: An UpdateContext: Invited update on the manageme...
-
People & PlacesDavid B. Granet, MD, FAAO, FACS, FAAPDavid B. Granet is the Anne Ratner Chair...
-
Videos & Visuals“TED Today” Episode 5https://www.facebook.com/ThyroidEyes/vid...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.